Stock A086450 DONGKOOK PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings DongKook Pharmaceutical Co., Ltd.

Equities

A086450

KR7086450004

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-11 pm EDT 		5-day change 1st Jan Change
18,480 KRW -0.11% Intraday chart for DongKook Pharmaceutical Co., Ltd. -5.08% +14.36%
May. 16 DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 14 DongKook Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DONGKOOK PHARMACEUTICAL CO., LTD. Stock DongKook Pharmaceutical Co., Ltd.
+14.36% 589M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.79% 780B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.76% 627B
B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.43% 334B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.18% 296B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.60% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-0.41% 217B
A+
NOVARTIS AG Stock Novartis AG
+11.54% 214B
B-
AMGEN INC. Stock Amgen Inc.
+4.53% 161B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.92% 159B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. A086450 Stock
  4. Ratings DongKook Pharmaceutical Co., Ltd.